Last updated 2026-06-18
- Went public, Apr 2003
- Raised $30M PIPE, Feb 2021
- Raised $54M debt round, Apr 2020
Total raised
$136.9M
Last: PIPE 2025-02
Stage
Public
Founded
2003
Headcount
258
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences
About
Pluri creates cell-based products for commercial use and aims to promote global wellbeing and sustainability. The company's technology platform, a patented and validated 3D cell expansion system, advances novel cell-based solutions for a range of initiatives, from medicine and climate change to food scarcity and animal cruelty. Pluri's method is accurate, scalable, cost effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food technology and aims to establish partnerships that leverage the company's 3D cell-based technology in additional industries that require effective, mass cell production.
Funding history · 10 rounds · $136.9M total
2015-06
Grant
$2.9M
2016-05
Grant
$3.3M
2016-10
PIPE
$30.0M
2017-01
PIPE
$15.0M
2017-09
Grant
$8.7M
2019-04
PIPE
$20.0M
2020-04
Debt Financing
$54.0M
2021-02
PIPE
$30.0M
2025-01
PIPE
$6.5M
2025-02
PIPE
$3.5M
Q&A
- What is Pluri's primary focus?
- Pluri specializes in creating cell-based products for commercial use, leveraging a patented 3D cell expansion system to develop solutions in regenerative medicine, food technology, and other industries.
- When did Pluri complete its most recent funding round?
- In February 2025, Pluri completed a PIPE funding round, raising $3.5 million from Merchant Adventure Fund LP.
- What was Pluri's second most recent funding event?
- In January 2025, Pluri secured $6.5 million in a PIPE funding round, with Alejandro Weinstein as the lead investor.
- Has Pluri made any acquisitions recently?
- Yes, Pluri acquired Kokomodo in January 2025 for $4.5 million.
- When did Pluri first go public on NASDAQ?
- Pluri went public on NASDAQ in April 2003 with a valuation of $200 million.
- What is the employee count for Pluri?
- Pluri has an employee count in the 201-500 range.
- Who is the current President & CEO of Pluri?
- Yaky Yanay serves as the President & CEO of Pluri.
- What are some of Pluri's key products?
- Pluri's key products include PLX-R18, PLX-PAD, and PLX-Immune.
Team · 7
President & CEO
Executive Chairman
Lior Raviv
VP Development & Operations
VP Quality Affairs
Director of Business, Investor and Public Relations
Marcom Manager
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Agriculture & FoodCropsHealthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
orthopedicsinflammatory-diseasespulmonarybiological-therapyregenerative-medicinestem-cellscell-therapybioprocesscardiovascularpharmaceuticals3d-technologyspace-techpharma-companiespatients
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | pluri-biotech.com/ |
|---|---|
| linkedin.com/company/226821 | |
| YouTube | youtube.com/channel/UC65WAbsbyKFNqvWWkfWZkKQ |
| Crunchbase | crunchbase.com/organization/pluristem-therapeutics |
Identifiers & details
| Former names | Pluristem Therapeutics |
|---|---|
| Founded | 2003-1 |
| Employees (exact) | 258 |
| Market cap | $27.7M |
| Status reason | Public on NASDAQ on Apr 2003;Public on TASE on Dec 2010; |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| 2025-01 | $4.5M |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2015-06 | $17.0M | |||
| 2010-12 | ||||
| 2003-04 |
Radar intelligence
Patents
| EPO | 20 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | pluri-biotech.com |
|---|